Loading…
Bafna Pharmaceuticals (BAFNAPH)₹472.80+2.00%Pharmaceuticals
At the end of the Jun 2026 quarter, Bafna Pharmaceuticals' shareholders were: promoters 74.97%, FIIs 9.30%, public 15.73%. Promoter holding is unchanged on the quarter. 0.00% of promoter shares were pledged. It had 7,063 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 88.70% | 88.39% | 88.26% | 88.26% | 88.26% | 88.26% | 74.97% | 74.97% | 74.97% | 74.97% | 74.97% | 74.97% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8.49% | 9.30% | 9.30% | 9.30% | 9.30% | 9.30% |
| Public | 11.30% | 11.61% | 11.74% | 11.74% | 11.74% | 11.74% | 16.54% | 15.73% | 15.73% | 15.73% | 15.73% | 15.73% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 7,355 | 7,368 | 7,540 | 7,392 | 7,296 | 7,215 | 7,143 | 7,284 | 7,573 | 7,120 | 6,929 | 7,063 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Srjr Lifesciences Llp | Promoter | 74.62% | 0.00 |
| M7 Global Fund Pcc-Aerion | FII | 3.18% | 0.00 |
| M7 Global Fund Pcc - Cell Dewcap Fund | FII | 3.13% | 0.00 |
| Zeal Global Opportunities Fund | FII | 3.00% | 0.00 |
| Alpana Mundra | Public | 2.70% | −0.52 |
| Monarch Networth Finserve Private Limited | Public | 1.34% | 0.00 |
| Guttikonda Vara Lakshmi | Public | 1.30% | 0.00 |
| P Paras Bafna | Promoter | 0.21% | 0.00 |
| Navin Bafna | Promoter | 0.18% | 0.00 |
| Mahaveer Chand Bafna | Promoter | 0.03% | 0.00 |
| Amri Bai Bafna | Promoter | 0.01% | 0.00 |
| Sasikala Bafna | Promoter | 0.01% | 0.00 |
Promoters held 74.97% of Bafna Pharmaceuticals at the end of the Jun 2026 quarter, the same as a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 9.30% (unchanged at 9.30% a quarter earlier) and domestic institutions (DIIs) held no reported stake.
No. The Jun 2026 filing shows no pledged promoter shares.
Bafna Pharmaceuticals had 7,063 shareholders at the end of the Jun 2026 quarter, against 7,284 a year earlier.
M7 Global Fund Pcc-Aerion (FII) held 3.18% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.